BackCollPlant Biotechnologies Overview
CollPlant Biotechnologies Ltd - Ordinary Shares New

CollPlant Biotechnologies Return on Equity

CollPlant Biotechnologies (CLGN) has a ROE of -268.81%, below the Healthcare sector average of 29.33%.

Get informed when a big investor buys or sells

+ Follow

ROE

-268.81%

Return on Equity

-268.81%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

CollPlant Biotechnologies (CLGN) FAQ

The latest ROE for CLGN is -268.81%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside CollPlant Biotechnologies's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CLGN currently prints -268.81% for ROE, while the sector average sits near 29.33%. That is roughly 1016.5% below the sector mean. Large gaps often invite a closer look at CollPlant Biotechnologies's growth, margins, and balance sheet.

Return on Equity shows how effectively CollPlant Biotechnologies converts resources into returns. At -268.81%, CLGN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CLGN's ROE (-268.81%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack CollPlant Biotechnologies's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.